$SPRO
Spero Therapeutics Inc

2019 Q4 Form 10-Q Financial Statement

#000156459019039770 Filed on November 04, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $696.0K $4.643M $658.0K
YoY Change -58.87% 605.62% 10.22%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.790M $4.130M $3.130M
YoY Change 3.84% 31.95% -14.25%
% of Gross Profit
Research & Development $25.73M $18.50M $8.459M
YoY Change 181.82% 118.64% 22.42%
% of Gross Profit
Depreciation & Amortization -$110.0K $490.0K $80.00K
YoY Change -178.57% 512.5% -11.11%
% of Gross Profit
Operating Expenses $29.51M $22.63M $11.59M
YoY Change 131.0% 95.19% 9.75%
Operating Profit -$17.99M -$10.94M
YoY Change 64.47% 9.72%
Interest Expense $1.550M $268.0K $472.0K
YoY Change -43.22% 280.65%
% of Operating Profit
Other Income/Expense, Net -$650.0K $268.0K $472.0K
YoY Change -232.65% -43.22% 286.89%
Pretax Income -$24.99M -$17.72M -$10.46M
YoY Change 135.75% 69.41% 6.3%
Income Tax
% Of Pretax Income
Net Earnings -$24.99M -$17.70M -$10.46M
YoY Change 135.74% 69.17% 6.37%
Net Earnings / Revenue -3589.94% -381.22% -1590.12%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.311M -$949.6K -$598.7K
COMMON SHARES
Basic Shares Outstanding 19.13M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.00M $93.90M $131.2M
YoY Change -28.94% -28.43% 416.54%
Cash & Equivalents $29.73M $45.60M $40.48M
Short-Term Investments $52.30M $48.30M $90.70M
Other Short-Term Assets $4.800M $2.700M $1.200M
YoY Change -36.0% 125.0% 20.0%
Inventory
Prepaid Expenses
Receivables $1.000M
Other Receivables $6.400M
Total Short-Term Assets $95.41M $104.0M $133.7M
YoY Change -23.19% -22.24% 395.94%
LONG-TERM ASSETS
Property, Plant & Equipment $2.273M $2.519M $2.200M
YoY Change -21.43% 14.5% 74.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.520M $2.077M $200.0K
YoY Change 111.92% 938.5% -91.67%
Total Long-Term Assets $10.69M $8.540M $2.420M
YoY Change 123.29% 252.89% -47.29%
TOTAL ASSETS
Total Short-Term Assets $95.41M $104.0M $133.7M
Total Long-Term Assets $10.69M $8.540M $2.420M
Total Assets $106.1M $112.5M $136.1M
YoY Change -17.75% -17.34% 331.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.147M $2.524M $1.364M
YoY Change 15.1% 85.04% -32.17%
Accrued Expenses $22.50M $12.30M $8.600M
YoY Change 171.08% 43.02% 91.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.66M $15.06M $10.28M
YoY Change 116.46% 46.51% 49.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.900M $4.400M $300.0K
YoY Change 512.5% 1366.67% -25.0%
Total Long-Term Liabilities $4.900M $4.400M $300.0K
YoY Change 512.5% 1366.67% -25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.66M $15.06M $10.28M
Total Long-Term Liabilities $4.900M $4.400M $300.0K
Total Liabilities $31.53M $19.48M $10.57M
YoY Change 139.75% 84.29% 45.3%
SHAREHOLDERS EQUITY
Retained Earnings -$199.4M -$174.4M -$127.9M
YoY Change 43.99% 36.39% 55.61%
Common Stock $274.0M $19.00K $18.00K
YoY Change 7.86% 5.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.57M $92.68M $125.2M
YoY Change
Total Liabilities & Shareholders Equity $106.1M $112.5M $136.1M
YoY Change -17.75% -17.34% 331.44%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income -$24.99M -$17.70M -$10.46M
YoY Change 135.74% 69.17% 6.37%
Depreciation, Depletion And Amortization -$110.0K $490.0K $80.00K
YoY Change -178.57% 512.5% -11.11%
Cash From Operating Activities -$17.37M -$9.660M -$5.520M
YoY Change 28.57% 75.0% -47.48%
INVESTING ACTIVITIES
Capital Expenditures -$120.0K -$20.00K -$20.00K
YoY Change -95.04% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$3.970M -$15.87M -$72.59M
YoY Change -140.93% -78.14%
Cash From Investing Activities -$4.100M -$15.89M -$72.61M
YoY Change -156.32% -78.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.600M 10.00K 69.90M
YoY Change -3211.11% -99.99% -17148.78%
NET CHANGE
Cash From Operating Activities -17.37M -9.660M -5.520M
Cash From Investing Activities -4.100M -15.89M -72.61M
Cash From Financing Activities 5.600M 10.00K 69.90M
Net Change In Cash -15.87M -25.54M -8.230M
YoY Change 147.58% 210.33% -24.63%
FREE CASH FLOW
Cash From Operating Activities -$17.37M -$9.660M -$5.520M
Capital Expenditures -$120.0K -$20.00K -$20.00K
Free Cash Flow -$17.25M -$9.640M -$5.500M
YoY Change 55.55% 75.27% -47.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001701108
CY2019Q3 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
1425000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
124219000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2519000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2893000
CY2018Q4 spro Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
233000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2018Q4 spro Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
922000
CY2018Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q4 us-gaap Other Receivables
OtherReceivables
376000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3676000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7478000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
103970000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
CY2019Q3 us-gaap Revenues
Revenues
4643000
CY2018Q3 us-gaap Revenues
Revenues
658000
us-gaap Revenues
Revenues
14517000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8459000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40047000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3134000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11803000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
11593000
us-gaap Operating Expenses
OperatingExpenses
51850000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10935000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37333000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
472000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1394000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45597000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei City Area Code
CityAreaCode
857
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Small Business
EntitySmallBusiness
true
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48259000
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Registrant Name
EntityRegistrantName
Spero Therapeutics, Inc.
dei Trading Symbol
TradingSymbol
SPRO
dei Local Phone Number
LocalPhoneNumber
242-1600
dei Entity File Number
EntityFileNumber
001-38266
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34080000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
115500000
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138502000
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19128146
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3220
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2720
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2720
CY2018Q3 spro Grant Revenue
GrantRevenue
658000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
112510000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129006000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
3220
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18663030
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17205962
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18663030
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17205962
CY2019Q3 spro Grant Revenue
GrantRevenue
4471000
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
442000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15058000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12318000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4162000
CY2019Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
256000
CY2018Q4 us-gaap Liabilities
Liabilities
13151000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
17000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
81363000
CY2019Q3 us-gaap Other Receivables
OtherReceivables
5013000
us-gaap Operating Expenses
OperatingExpenses
33996000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31722000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9238000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3944000
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2077000
CY2019Q3 us-gaap Assets
Assets
112510000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2524000
CY2019Q3 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
11869000
CY2019Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
223000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
229000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
833000
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
267083000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
254013000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18000
CY2019Q3 us-gaap Minority Interest
MinorityInterest
355000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
355000
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
93034000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
115855000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4046000
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseMember
us-gaap Revenues
Revenues
2274000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24758000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
268000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
472000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1394000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
659000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
659000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-17717000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.95
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18659079
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-23000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-6000
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
12000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4133000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2018Q4 us-gaap Assets
Assets
129006000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3603000
CY2018Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8263000
CY2019Q3 us-gaap Liabilities
Liabilities
19476000
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
19000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174441000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
92679000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18495000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17985000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
22628000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-10463000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.60
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17471462
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
268000
us-gaap Profit Loss
ProfitLoss
-35939000
us-gaap Profit Loss
ProfitLoss
-31063000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.01
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17859829
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15417087
spro Grant Revenue
GrantRevenue
10471000
spro Grant Revenue
GrantRevenue
2274000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
172000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-8000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
46000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-23000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17705000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10471000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35893000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31086000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
861000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
270000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-248000
us-gaap Share Based Compensation
ShareBasedCompensation
2847000
us-gaap Share Based Compensation
ShareBasedCompensation
1980000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-164000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-237000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
663000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
346000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
4637000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-679000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3802000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-706000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
319000
spro Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-980000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
432000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1041000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2088000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2749000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2372000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-91000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-44000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32653000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26116000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
76523000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
104421000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
110337000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
14000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33629000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90443000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10289000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70500000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
158000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
996000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
410000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
197000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10541000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
69701000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11517000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-46858000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34080000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87338000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45597000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40480000
spro Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
246000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109669000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1980000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
981000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
410000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9815000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2847000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
65668000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
146000
CY2018Q3 spro Common And Preferred Stock Issued During Period Value Net Of Issuance Costs
CommonAndPreferredStockIssuedDuringPeriodValueNetOfIssuanceCosts
69504000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
705000
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
125552000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
84957000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
197000
spro Common And Preferred Stock Issued During Period Value Net Of Issuance Costs
CommonAndPreferredStockIssuedDuringPeriodValueNetOfIssuanceCosts
69504000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
917000
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim Financial Information</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated balance sheet at December&#160;31, 2018 was derived from audited financial statements, but does not include all disclosures required by GAAP. The accompanying unaudited condensed consolidated financial statements as of September&#160;30, 2019, and for the three and nine months ended September&#160;30, 2019 and 2018, have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and the notes thereto for the year ended December&#160;31, 2018, included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2018,&#160;on file with the SEC. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company&#8217;s financial position as of September&#160;30, 2019, and results of operations for the three and nine months ended September&#160;30, 2019 and 2018, and cash flows for the nine months ended September&#160;30, 2019 and 2018 have been made. The results of operations for the three and nine months ended September&#160;30, 2019 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2019.</p>
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
554000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3635225
CY2019Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
371443
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
981000
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
705000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5864930
us-gaap Use Of Estimates
UseOfEstimates
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses, and the valuation of share-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</p>
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
81363000
CY2019Q3 us-gaap Lease Cost
LeaseCost
464000
us-gaap Lease Cost
LeaseCost
1219000
us-gaap Operating Lease Payments
OperatingLeasePayments
1006000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1267000
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentMember
CY2019Q3 spro Operating And Finance Lease Assets
OperatingAndFinanceLeaseAssets
5211000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4604000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
228000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
928000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
943000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1061000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1076000
CY2019Q3 spro Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
1092000
CY2019Q3 spro Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
1108000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6436000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1832000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1361000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4406378
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5864930
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4406378
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1054000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
995000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1107000
spro Entity Incorporation Month And Year
EntityIncorporationMonthAndYear
2013-12
us-gaap Business Acquisition Date Of Acquisition Agreement1
BusinessAcquisitionDateOfAcquisitionAgreement1
2017-06-30
spro Business Combination Exchange Ratio
BusinessCombinationExchangeRatio
1
CY2019Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2100000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5400000
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
48241000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
19000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
48259000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
81391000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
28000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1123000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
2246000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7886000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2019Q3 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
8364000
CY2018Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4541000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2315000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2379000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
636000

Files In Submission

Name View Source Status
0001564590-19-039770-index-headers.html Edgar Link pending
0001564590-19-039770-index.html Edgar Link pending
0001564590-19-039770.txt Edgar Link pending
0001564590-19-039770-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-10q_20190930.htm Edgar Link pending
spro-20190930.xml Edgar Link completed
spro-20190930.xsd Edgar Link pending
spro-20190930_cal.xml Edgar Link unprocessable
spro-20190930_def.xml Edgar Link unprocessable
spro-20190930_lab.xml Edgar Link unprocessable
spro-20190930_pre.xml Edgar Link unprocessable
spro-ex311_9.htm Edgar Link pending
spro-ex312_10.htm Edgar Link pending
spro-ex321_8.htm Edgar Link pending
spro-ex322_6.htm Edgar Link pending